Latest Chromadex Corp (CDXC) Headlines
ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
PR Newswire - Thu Mar 06, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Feb 27, 8:59AM CST
RedChip Companies, Inc. ("RedChip"), an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, February 27, 2014 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg U.K. Saturday, March 1, 2014 at 12:30 a.m. GMT; on Bloomberg Europe Sunday, March 2, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 2, 2014 at 3:30 p.m. HKT.
Public Outcry Over Mavuno Church "Gerrit" Poster
by Khikami Obbayi - All Africa Global Media - Wed Feb 26, 12:01AM CST
The Mavuno Church over the weekend put up a controversial poster which has been trending on Social Media as people weigh in on the debate of the appropriateness of the poster's design. The poster which is an advert for a series of sermons to be held during services for the month of March incorporates a picture of would be teens in a presumably intimate position together with titles to secular songs including a controversial book title.
ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST
PR Newswire - Fri Jan 17, 7:30AM CST
ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.
ChromaDex CEO Frank Jaksch to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Mon Jan 06, 9:12AM CST
ChromaDex(R) Corporation (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today its CEO Frank Jaksch will be interviewed live today by Michal Yorba on Clear Channel Business Talk Radio's The Traders Network. The interview will air on Monday, January 6, 2014, at 2:45pm CST / 12:45pm PST / 3:45pm EST.
ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX®
PR Newswire - Mon Jan 06, 7:30AM CST
ChromaDex Corporation® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a four year ingredient supply and brand licensing agreement valued at approximately $62 million, with 5LINX®, one of the largest and fastest-growing direct marketing companies in the world.
ChromaDex® Appoints Former Nestle Executive to Its Board of Directors
PR Newswire - Fri Jan 03, 7:30AM CST
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today an addition to its board of directors with the appointment of Steve Allen as an independent director.
International Stevia Council and ChromaDex Enter Into Agreement for Reference Benchmark Standard
PR Newswire - Wed Dec 18, 7:25AM CST
The International Stevia Council (ISC) and ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, have entered into an agreement whereby ChromaDex is to provide, for the next two years, the Reference Benchmark Standard in the ISC's Proficiency Testing Program (PTP) for stevia leaf extracts.
ChromaDex® Updates Research Activity Agreements For Its NIAGEN(TM) Nicotinamide Riboside
PR Newswire - Fri Nov 22, 7:30AM CST
ChromaDex Corporation® (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced an update on recent material transfer agreement activity with significant universities and research institutes for its NIAGEN(TM) nicotinamide riboside (NR).
ChromaDex® Reports Results for the Third Quarter 2013
PR Newswire - Thu Nov 21, 4:50PM CST
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today financial results for the third quarter ended September 28, 2013.
Universite Libre de Bruxelles and ChromaDex® To Collaborate on NIAGEN(TM) Nicotinamide Riboside Research
PR Newswire - Tue Nov 05, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Universite Libre de Bruxelles (ULB), whereby ChromaDex will provide ULB with quantities of its recently launched NIAGEN(TM) nicotinamide riboside (NR).
ChromaDex Corp awarded ISO/IEC 17025:2005 certification for quality and excellence in testing practices
M2 - Thu Oct 31, 8:11AM CDT
Natural products company ChromaDex Corp (OTCQB:CDXC) reported on Wednesday the receipt of the internationally recognized ISO (International Organisation for Standardization) and IEC (International Electrotechnical Commission) 17025:2005 accreditation.
ChromaDex® Receives ISO/IEC 17025:2005 Certification
PR Newswire - Wed Oct 30, 7:20AM CDT
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that the ChromaDex analytics laboratory located in Boulder, Colorado has received the internationally recognized ISO (International Organization for Standardization) and IEC (International Electrotechnical Commission) 17025:2005 accreditation.
ChromaDex Receives Strategic Investment From DSM Venturing
PR Newswire - Mon Oct 21, 5:30AM CDT
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that it has received equity financing from DSM Venturing, the corporate venture arm of Royal DSM (NYSE Euronext Amsterdam: DSM), the global life sciences and material sciences company.
OTC Daily Alert Stock Watch - ChromaDex Inc. (OTCQB: CDXC)
WorldStockWire - Thu Aug 15, 9:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ChromaDex® Reports Results for the Second Quarter 2013
PR Newswire - Tue Aug 13, 7:20AM CDT
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today financial results for the second quarter ended June 29, 2013.
ChromaDex reports new exclusive worldwide patent rights to skin care product, pTeroPure Pterostilbene
M2 - Tue Aug 06, 6:41AM CDT
Natural products company ChromaDex Corporation (OTC Markets:CDXC) said on Monday that it has licensed the exclusive worldwide patent rights related to pharmaceutical and cosmetic preparations of pterostilbene for topical application for prevention and/or treatment of skin diseases, damage or injuries, including those relating to aging and exposure to the sun.
ChromaDex® Acquires New Exclusive Worldwide Patent Rights for pTeroPure® Pterostilbene Relating to Skin Care
PR Newswire - Mon Aug 05, 7:20AM CDT
ChromaDex Corporation® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed from Green Molecular, S.L. exclusive worldwide patent rights related to pharmaceutical and cosmetic preparations of pterostilbene for topical application for prevention and/or treatment of skin diseases, damage or injuries, including those relating to aging and exposure to the sun.
ChromaDex® Enters into Agreement with Beckman Research Institute of City of Hope to Supply pTeroPure(TM) Pterostilbene for Cancer Research
PR Newswire - Mon Jul 29, 7:20AM CDT
ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Beckman Research Institute of City of Hope ("BRICOH") whereby ChromaDex will provide BRICOH with quantities of its branded pTeroPure(TM) pterostilbene to be used in preclinical in vitro and mouse model experiments to study its potential therapeutic use for treatment of ovarian, uterine and breast cancer.
ChromaDex® Announces Deal For Its Recently Launched Niagen(TM) Nicotinamide Riboside With Thorne Research
PR Newswire - Mon Jul 08, 7:25AM CDT
ChromaDex Corp.® (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, today announced a three-year marketing deal worth at least $3.5 million with Thorne Research Inc. for ChromaDex's recently launched Niagen(TM), its novel, patented branded nicotinamide riboside (NR) ingredient.
ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
PR Newswire - Thu Mar 06, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu Feb 27, 8:59AM CST
RedChip Companies, Inc. ("RedChip"), an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, February 27, 2014 at 10:00 p.m. Pacific (1 a.m. EST). The show will also air on Bloomberg U.K. Saturday, March 1, 2014 at 12:30 a.m. GMT; on Bloomberg Europe Sunday, March 2, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday March 2, 2014 at 3:30 p.m. HKT.
Public Outcry Over Mavuno Church "Gerrit" Poster
by Khikami Obbayi - All Africa Global Media - Wed Feb 26, 12:01AM CST
The Mavuno Church over the weekend put up a controversial poster which has been trending on Social Media as people weigh in on the debate of the appropriateness of the poster's design. The poster which is an advert for a series of sermons to be held during services for the month of March incorporates a picture of would be teens in a presumably intimate position together with titles to secular songs including a controversial book title.
ChromaDex CEO to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference on Wednesday, January 22nd at 8:30 am EST
PR Newswire - Fri Jan 17, 7:30AM CST
ChromaDex Corp.® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at "TEN," Noble Financial Capital Markets' Tenth Annual Equity Conference at Club Med in Sandpiper Bay, Florida in Room 2 on Wednesday, January 22, 2014 at 8:30 am EST.
ChromaDex CEO Frank Jaksch to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM
Marketwire - Mon Jan 06, 9:12AM CST
ChromaDex(R) Corporation (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today its CEO Frank Jaksch will be interviewed live today by Michal Yorba on Clear Channel Business Talk Radio's The Traders Network. The interview will air on Monday, January 6, 2014, at 2:45pm CST / 12:45pm PST / 3:45pm EST.
ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX®
PR Newswire - Mon Jan 06, 7:30AM CST
ChromaDex Corporation® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a four year ingredient supply and brand licensing agreement valued at approximately $62 million, with 5LINX®, one of the largest and fastest-growing direct marketing companies in the world.
ChromaDex® Appoints Former Nestle Executive to Its Board of Directors
PR Newswire - Fri Jan 03, 7:30AM CST
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today an addition to its board of directors with the appointment of Steve Allen as an independent director.
International Stevia Council and ChromaDex Enter Into Agreement for Reference Benchmark Standard
PR Newswire - Wed Dec 18, 7:25AM CST
The International Stevia Council (ISC) and ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, have entered into an agreement whereby ChromaDex is to provide, for the next two years, the Reference Benchmark Standard in the ISC's Proficiency Testing Program (PTP) for stevia leaf extracts.
ChromaDex® Updates Research Activity Agreements For Its NIAGEN(TM) Nicotinamide Riboside
PR Newswire - Fri Nov 22, 7:30AM CST
ChromaDex Corporation® (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced an update on recent material transfer agreement activity with significant universities and research institutes for its NIAGEN(TM) nicotinamide riboside (NR).
ChromaDex® Reports Results for the Third Quarter 2013
PR Newswire - Thu Nov 21, 4:50PM CST
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today financial results for the third quarter ended September 28, 2013.
Universite Libre de Bruxelles and ChromaDex® To Collaborate on NIAGEN(TM) Nicotinamide Riboside Research
PR Newswire - Tue Nov 05, 7:20AM CST
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Universite Libre de Bruxelles (ULB), whereby ChromaDex will provide ULB with quantities of its recently launched NIAGEN(TM) nicotinamide riboside (NR).
ChromaDex Corp awarded ISO/IEC 17025:2005 certification for quality and excellence in testing practices
M2 - Thu Oct 31, 8:11AM CDT
Natural products company ChromaDex Corp (OTCQB:CDXC) reported on Wednesday the receipt of the internationally recognized ISO (International Organisation for Standardization) and IEC (International Electrotechnical Commission) 17025:2005 accreditation.
ChromaDex® Receives ISO/IEC 17025:2005 Certification
PR Newswire - Wed Oct 30, 7:20AM CDT
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that the ChromaDex analytics laboratory located in Boulder, Colorado has received the internationally recognized ISO (International Organization for Standardization) and IEC (International Electrotechnical Commission) 17025:2005 accreditation.
ChromaDex Receives Strategic Investment From DSM Venturing
PR Newswire - Mon Oct 21, 5:30AM CDT
ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that it has received equity financing from DSM Venturing, the corporate venture arm of Royal DSM (NYSE Euronext Amsterdam: DSM), the global life sciences and material sciences company.
OTC Daily Alert Stock Watch - ChromaDex Inc. (OTCQB: CDXC)
WorldStockWire - Thu Aug 15, 9:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ChromaDex® Reports Results for the Second Quarter 2013
PR Newswire - Tue Aug 13, 7:20AM CDT
ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today financial results for the second quarter ended June 29, 2013.
ChromaDex reports new exclusive worldwide patent rights to skin care product, pTeroPure Pterostilbene
M2 - Tue Aug 06, 6:41AM CDT
Natural products company ChromaDex Corporation (OTC Markets:CDXC) said on Monday that it has licensed the exclusive worldwide patent rights related to pharmaceutical and cosmetic preparations of pterostilbene for topical application for prevention and/or treatment of skin diseases, damage or injuries, including those relating to aging and exposure to the sun.
ChromaDex® Acquires New Exclusive Worldwide Patent Rights for pTeroPure® Pterostilbene Relating to Skin Care
PR Newswire - Mon Aug 05, 7:20AM CDT
ChromaDex Corporation® (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed from Green Molecular, S.L. exclusive worldwide patent rights related to pharmaceutical and cosmetic preparations of pterostilbene for topical application for prevention and/or treatment of skin diseases, damage or injuries, including those relating to aging and exposure to the sun.
ChromaDex® Enters into Agreement with Beckman Research Institute of City of Hope to Supply pTeroPure(TM) Pterostilbene for Cancer Research
PR Newswire - Mon Jul 29, 7:20AM CDT
ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Beckman Research Institute of City of Hope ("BRICOH") whereby ChromaDex will provide BRICOH with quantities of its branded pTeroPure(TM) pterostilbene to be used in preclinical in vitro and mouse model experiments to study its potential therapeutic use for treatment of ovarian, uterine and breast cancer.
ChromaDex® Announces Deal For Its Recently Launched Niagen(TM) Nicotinamide Riboside With Thorne Research
PR Newswire - Mon Jul 08, 7:25AM CDT
ChromaDex Corp.® (OTCBB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, today announced a three-year marketing deal worth at least $3.5 million with Thorne Research Inc. for ChromaDex's recently launched Niagen(TM), its novel, patented branded nicotinamide riboside (NR) ingredient.
